Ideaya Biosciences reports Q4 EPS ($1.49), consensus (62c)

Reports Q4 revenue $7M, consensus $4.31M. The net loss for the three months ended December 31, 2024, was $130.3M compared to the net loss of $34M for the three months ended December 31, 2023. Total stock compensation expense for the three months ended December 31, 2024, was $9.5M compared to $4.8M for the same period in 2023. Collaboration revenue for the three months ended December 31, 2024 totaled $7M compared to $3.9M for the three months ended December 31, 2023. Collaboration revenue was recognized for a $7M milestone payment from GSK that was earned for the IND clearance of IDE275 in October 2024. “We are excited to be targeting multiple clinical data readouts and program updates across our clinical pipeline in 2025, including the darovasertib neoadjuvant UM data update in the first half and median PFS readout in HLA-A2 negative 1L MUM by year-end, update on the Werner Helicase inhibitor program IDE275 at a major medical conference in the first half, clinical combination results from the IDE397 and Trodelvy combination in MTAP-deletion UC where the Gilead collaboration has expanded to evaluate both UC and NSCLC, among others. Next, we are excited to target a clinical data update for potential first-in-class DLL3 TOP1 ADC IDE849 in SCLC in 2025, including potentially at a medical conference, and we believe the clinical profile observed supports a potential monotherapy regulatory path in SCLC,” said Yujiro Hata, president and CEO, Ideaya Biosciences (IDYA).